MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/bs.pbr.2020.07.008

Медицинская библиотека · Progress in brain research · 2020

Evidence on the neuroprotective properties of brimonidine in glaucoma.

Scuteri Damiana, Bagetta Giacinto, Nucci Carlo, Aiello Francesco, Cesareo Massimo, Tonin Paolo, Corasaniti Maria Tiziana

СтатьяМетаанализПоддержка исследования: вне правительства СШАСистематический обзорПеревод пока не подготовлен

Аннотация

BACKGROUND

glaucoma is the leading cause of irreversible blindness all over the world. The degree of visual field loss accounts for the severity of the disease and represents the main clinical outcome of treatment for patients affected by glaucoma. The α2 agonists, like brimonidine, emerged in the 1960s as topical ophthalmologic treatment. Their neuroprotective mechanism in glaucoma is still debated, ranging from effect on extracellular glutamate, to ocular hypotension and blood flow.

OBJECTIVES

this systematic review and meta-analysis aims at assessing the efficacy of brimonidine on visual field deterioration during glaucoma through the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) approach. Databases consulted: the literature search has been performed on PubMed, MEDLINE, ClinicalTrials.gov and Scopus up to June 10th, 2020. Study eligibility criteria, participants, and interventions: clinical trials assessing the effects of brimonidine on visual field in patients with glaucoma. Study appraisal: the eligibility of the studies has been assessed by two independent authors and the selection has followed the PRISMA flow diagram. The retrieved results have been subjected to risk of bias evaluation.

RESULTS

the search of literature has retrieved 418 papers, among which 5 are eligible for inclusion in the qualitative analysis. All the studies present high heterogeneity, therefore meta-analysis has not been possible. The results obtained suggest that brimonidine improves visual field, but the design of the clinical trials rises some concerns in terms of risk of bias.

CONCLUSIONS

the evidence of neuroprotective effect of brimonidine is inconclusive and needs stronger support. Large double-blind randomized clinical trials are necessary to strengthen this evidence.

Для цитирования: Scuteri Damiana, Bagetta Giacinto, Nucci Carlo, Aiello Francesco, Cesareo Massimo, Tonin Paolo, Corasaniti Maria Tiziana. Evidence on the neuroprotective properties of brimonidine in glaucoma.. Progress in brain research. 2020. DOI: 10.1016/bs.pbr.2020.07.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.